KR20120127580A - 저메틸화제 및 히스톤 데아세틸라아제 저해제를 함유하는 약학 조성물 - Google Patents

저메틸화제 및 히스톤 데아세틸라아제 저해제를 함유하는 약학 조성물 Download PDF

Info

Publication number
KR20120127580A
KR20120127580A KR1020127017074A KR20127017074A KR20120127580A KR 20120127580 A KR20120127580 A KR 20120127580A KR 1020127017074 A KR1020127017074 A KR 1020127017074A KR 20127017074 A KR20127017074 A KR 20127017074A KR 20120127580 A KR20120127580 A KR 20120127580A
Authority
KR
South Korea
Prior art keywords
hdaci
composition
cladribine
transdermal patch
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127017074A
Other languages
English (en)
Korean (ko)
Inventor
엘리어트 엠. 에프너
루크 엠. 본
Original Assignee
님블 에피테크, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 님블 에피테크, 엘엘씨 filed Critical 님블 에피테크, 엘엘씨
Publication of KR20120127580A publication Critical patent/KR20120127580A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127017074A 2009-12-02 2010-04-30 저메틸화제 및 히스톤 데아세틸라아제 저해제를 함유하는 약학 조성물 Ceased KR20120127580A (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US28330509P 2009-12-02 2009-12-02
US61/283,305 2009-12-02
US30195610P 2010-02-05 2010-02-05
US61/301,956 2010-02-05
US32008310P 2010-04-01 2010-04-01
US61/320,083 2010-04-01
US12/769,913 US8491927B2 (en) 2009-12-02 2010-04-29 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US12/769,913 2010-04-29
US13/513,327 US10434090B2 (en) 2009-12-02 2010-04-30 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
PCT/US2010/001287 WO2011068522A1 (en) 2009-12-02 2010-04-30 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor

Publications (1)

Publication Number Publication Date
KR20120127580A true KR20120127580A (ko) 2012-11-22

Family

ID=44069079

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127017074A Ceased KR20120127580A (ko) 2009-12-02 2010-04-30 저메틸화제 및 히스톤 데아세틸라아제 저해제를 함유하는 약학 조성물

Country Status (9)

Country Link
US (3) US8491927B2 (cg-RX-API-DMAC7.html)
EP (1) EP2506814A4 (cg-RX-API-DMAC7.html)
JP (1) JP6002040B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120127580A (cg-RX-API-DMAC7.html)
CN (1) CN102711686A (cg-RX-API-DMAC7.html)
AU (1) AU2010326699B2 (cg-RX-API-DMAC7.html)
CA (1) CA2782205A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012006128A (cg-RX-API-DMAC7.html)
WO (1) WO2011068522A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2013162054A1 (ja) * 2012-04-24 2013-10-31 公立大学法人首都大学東京 クロマチン構造を制御する組成物
JP6243102B2 (ja) * 2012-05-01 2017-12-06 株式会社ジェムインターナショナル 貼付剤
FR2993461B1 (fr) * 2012-07-19 2014-08-08 Genethon Utilisation de composes modifiant l'epigenome pour le traitement des maladies genetiques musculaires liees a une anomalie de conformation proteique
WO2014022524A1 (en) * 2012-07-31 2014-02-06 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20140142522A1 (en) * 2012-11-16 2014-05-22 NU Technology, LLC Moist dressing with honeycomb pattern and drain channels
JP6626085B2 (ja) * 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
JP7158104B2 (ja) 2016-07-15 2022-10-21 ビラクタ セラピューティクス，インク． Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
EP4041750A4 (en) * 2019-10-07 2023-11-01 Viracta Subsidiary, Inc. DOSAGE FOR HDAC TREATMENT WITH REDUCED SIDE EFFECTS
US20220087948A1 (en) * 2020-09-18 2022-03-24 Nanovibronix, Inc. Transdermal patch of a portable ultrasound-generating system for improved delivery of therapeutic agents and associated methods of treatment

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
JPS62126123A (ja) * 1985-11-28 1987-06-08 Shigeki Suzuki バルプロ酸の経皮吸収方法
AU2514292A (en) 1991-08-27 1993-03-16 Cygnus Therapeutic Systems Transdermal formulations for administering prazosin
US6032073A (en) 1995-04-07 2000-02-29 Novartis Ag Iontophoretic transdermal system for the administration of at least two substances
US5736154A (en) * 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
AU5495798A (en) * 1997-01-16 1998-08-07 Sekisui Chemical Co., Ltd. External preparations for percutaneous absorption
SK20012000A3 (sk) 1998-06-29 2001-08-06 Pharmaceuticals Applications Asociates, Llc Transdermálny prostriedok na zmiernenie bolesti
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
AU7788701A (en) 2000-07-14 2002-01-30 Transform Pharmaceuticals Inc System and method for optimizing tissue barrier transfer of compounds
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
ATE487456T1 (de) 2001-12-13 2010-11-15 Vital Health Sciences Pty Ltd Transdermaler transport von verbindungen
US6841565B1 (en) 2002-03-29 2005-01-11 The Ohio State University Treatment of patients with chronic lymphocytic leukemia
CA2525764C (en) 2003-05-20 2012-07-17 Novartis Ag N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
EP1646628A1 (en) 2003-07-08 2006-04-19 Novartis AG Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
JP4884230B2 (ja) 2003-11-26 2012-02-29 ノバルティス アーゲー 有機化合物
WO2005065668A2 (en) 2003-12-29 2005-07-21 Qlt Usa, Inc. Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
US20050255150A1 (en) * 2004-04-26 2005-11-17 Cassel Douglas R Wound treatment patch for alleviating pain
KR100602434B1 (ko) 2004-09-10 2006-07-19 최상식 복수 개의 단위 구획을 포함하는 약물의 경피 투여용 패치
AU2006283677A1 (en) 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070197957A1 (en) 2005-10-03 2007-08-23 Hunter William L Implantable sensors, implantable pumps and anti-scarring drug combinations
US9186339B2 (en) 2005-11-16 2015-11-17 Universidad Nacional Autonoma De Mexico Use of transcriptome modifying agents and chemotherapy or radiotherapy against cancer
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
US20110077215A1 (en) 2005-12-07 2011-03-31 The University Of Utah Research Foundation DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL)
AU2006339445A1 (en) 2006-03-02 2007-09-07 Agency For Science, Technology And Research Methods for cancer therapy and stem cell modulation
US8585753B2 (en) 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
US8338416B2 (en) * 2006-03-16 2012-12-25 Pharmacylics, Inc. Indole derivatives as inhibitors of histone deacetylase
ES2444890T3 (es) 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam Nueva composición para el control del crecimiento tumoral
AU2007247571A1 (en) * 2006-05-05 2007-11-15 Coloplast A/S A pressure sensitive adhesive composition comprising cross-linked polyalkylene oxide and water absorbent hydrophilic agents
WO2008082646A2 (en) 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use
US20100069458A1 (en) 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
WO2008116163A1 (en) 2007-03-22 2008-09-25 Oregon Health & Science University Therapeutic drug combinations for treatment of b-cell malignancies
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
US20090025274A1 (en) 2007-07-23 2009-01-29 Tim Lail Animal trap
JP2011500086A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
WO2009067543A2 (en) 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
US9228172B2 (en) 2008-06-19 2016-01-05 The Trustees Of The University Of Pennsylvania Inducible regulatory T-cell generation for hematopoietic transplants
WO2010020787A1 (en) 2008-08-22 2010-02-25 Oncomethylome Sciences Sa Diagnosis and treatment of tumours
TWI546537B (zh) * 2009-05-19 2016-08-21 維維亞生技公司 提供針對血液腫瘤之體外個人化藥物測試之方法
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
JP5548470B2 (ja) * 2010-02-16 2014-07-16 日本碍子株式会社 ハニカム触媒体
WO2011113013A2 (en) * 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
WO2012044936A1 (en) * 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
RS54648B1 (sr) * 2010-11-12 2016-08-31 Pharma Mar S.A. Kombinovana terapija sa antitumorskim alkaloidom
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
WO2013043232A2 (en) * 2011-04-08 2013-03-28 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h) -ones for the treatment of nervous system disorders and cancer
US10941399B2 (en) * 2011-04-14 2021-03-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
WO2012149014A1 (en) * 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
MX2014000130A (es) * 2011-06-28 2014-05-01 Pharmacyclics Inc Procedimientos y composiciones para la inhibicion de resorcion osea.
TW201700103A (zh) * 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
WO2013086451A2 (en) * 2011-12-09 2013-06-13 Afraxis, Inc. Pak inhibitors for the treatment of cancer
US8921367B2 (en) * 2012-05-31 2014-12-30 Amgen Inc. Use of AMG 900 for the treatment of cancer
KR20210033067A (ko) * 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014009318A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
ES2885769T3 (es) * 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
AU2013299627C1 (en) * 2012-08-09 2018-05-31 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CN104379169A (zh) * 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20140120083A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量

Also Published As

Publication number Publication date
CA2782205A1 (en) 2011-06-09
JP2013512898A (ja) 2013-04-18
US20200222379A1 (en) 2020-07-16
MX2012006128A (es) 2012-09-07
US20120310183A1 (en) 2012-12-06
US8491927B2 (en) 2013-07-23
AU2010326699B2 (en) 2016-01-07
JP6002040B2 (ja) 2016-10-05
AU2010326699A1 (en) 2012-07-19
EP2506814A1 (en) 2012-10-10
CN102711686A (zh) 2012-10-03
EP2506814A4 (en) 2013-05-22
US20110129521A1 (en) 2011-06-02
WO2011068522A1 (en) 2011-06-09
US10434090B2 (en) 2019-10-08

Similar Documents

Publication Publication Date Title
AU2010326699B2 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20240293521A1 (en) Combination use of wt1 antigen peptide and immunomodulator
EP2603222B1 (en) Combinatory cancer treatment
WO2020257283A1 (en) Nicotinyl riboside compounds and their uses
WO2018236814A2 (en) NICOTINAMIDE RIBOSID DERIVATIVES AND USES THEREOF
ES2913119T3 (es) Cerdulatinib para tratar mieloma
JP2013512898A5 (cg-RX-API-DMAC7.html)
JP2016517434A5 (cg-RX-API-DMAC7.html)
CN106535900A (zh) 使用braf抑制剂的伤口愈合
KR20230009426A (ko) 암을 처치하기 위한 의약 조성물
CA3224544A1 (en) Treatment of immune-related disorders, kidney disorders, liver disorders, hemolytic disorders, and oxidative stress-associated disorders using nrh, narh and reduced derivatives thereof
US20250099545A1 (en) Compositions, systems, and methods for treating cancer using tumor treating fields with immune checkpoint inhibitors and mhc class i activators
WO2014022524A1 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP1847274A1 (en) Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy
WO2016053989A2 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
Chatterji et al. Microtubules as Anti-Cancer Drug Targets
KR20250080902A (ko) Cd73 화합물의 동결건조된 제형
HK40084495A (en) Pharmaceutical composition for treating cancer
TR202002325A2 (tr) Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-4
HK1250213B (en) Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
Wang Metabolic reprogramming in non-small cell lung cancer: from mechanism to drug therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120629

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150428

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160818

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160818

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I